FY25 consensus $119/5M. Cites delayed Etorel rollout and government procurement-related uncertainty.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
- Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
- Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
- Gyre Therapeutics initiated with a Buy at Jefferies
- Gyre Therapeutics Announces Positive Phase 3 Results